|Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats|
H Liu, J Yang, F Du, X Gao, X Ma, Y Huang, F Xu, W Niu, F Wang, Y Mao, ...
Drug Metabolism and Disposition 37 (12), 2290-2298, 2009
|Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach|
L Xu, T Lu, L Tuomi, N Jumbe, J Lu, S Eppler, P Kuebler, ...
Investigative ophthalmology & visual science 54 (3), 1616-1624, 2013
|Comparative pharmacokinetics of baicalin after oral administration of pure baicalin,< i> Radix scutellariae</i> extract and Huang-Lian-Jie-Du-Tang to rats|
T Lu, J Song, F Huang, Y Deng, L Xie, G Wang, X Liu
Journal of ethnopharmacology 110 (3), 412-418, 2007
|Plasma and urinary tanshinol from Salvia miltiorrhiza (Danshen) can be used as pharmacokinetic markers for cardiotonic pills, a cardiovascular herbal medicine|
T Lu, J Yang, X Gao, P Chen, F Du, Y Sun, F Wang, F Xu, H Shang, ...
Drug Metabolism and Disposition 36 (8), 1578-1586, 2008
|Simultaneous determination of berberine and palmatine in rat plasma by HPLC–ESI-MS after oral administration of traditional Chinese medicinal preparation Huang-Lian-Jie-Du …|
T Lu, Y Liang, J Song, L Xie, GJ Wang, XD Liu
Journal of pharmaceutical and biomedical analysis 40 (5), 1218-1224, 2006
|Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study|
O Al-Sawaf, C Zhang, T Lu, MZ Liao, A Panchal, S Robrecht, T Ching, ...
Journal of Clinical Oncology 39 (36), 4049-4060, 2021
|Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab|
JF Seymour, TJ Kipps, BF Eichhorst, J D’Rozario, CJ Owen, S Assouline, ...
Blood, The Journal of the American Society of Hematology 140 (8), 839-850, 2022
|A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities|
D Lu, T Lu, M Stroh, RA Graham, P Agarwal, L Musib, CC Li, BL Lum, ...
Cancer chemotherapy and pharmacology 77, 459-476, 2016
|‘LC‐electrolyte effects’ improve the bioanalytical performance of liquid chromatography/tandem mass spectrometric assays in supporting pharmacokinetic study for drug discovery|
L Wang, Y Sun, F Du, W Niu, T Lu, J Kan, F Xu, K Yuan, T Qin, C Liu, C Li
Rapid Communications in Mass Spectrometry: An International Journal Devoted …, 2007
|Pharmacokintics of the Ginkgo Bfollowing intravenous administration of Ginkgo B emulsion in rats|
WD Chen, Y Liang, L Xie, T Lu, XD Liu, GJ Wang
Biological and Pharmaceutical Bulletin 30 (1), 1-5, 2007
|High‐performance liquid chromatographic method for the determination and pharmacokinetic study of wogonoside in rat serum after oral administration of traditional Chinese …|
YX Deng, T Lu, L Xie, XD Liu
Biomedical Chromatography 20 (10), 1098-1102, 2006
|Development of a physiologically based pharmacokinetic model for itraconazole pharmacokinetics and drug–drug interaction prediction|
Y Chen, F Ma, T Lu, N Budha, JY Jin, JR Kenny, H Wong, CECA Hop, ...
Clinical pharmacokinetics 55, 735-749, 2016
|Simple, sensitive and rapid liquid chromatography/atmospheric pressure chemical ionization mass spectrometric method for the quantitation of Ranolazine in rat plasma|
Y Liang, L Xie, XD Liu, WD Chen, T Lu, Y Xiong, GJ Wang
Rapid Communications in Mass Spectrometry: An International Journal Devoted …, 2006
|Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma|
T Lu, L Gibiansky, X Li, C Li, R Shi, P Agarwal, J Hirata, D Miles, P Chanu, ...
Leukemia & Lymphoma 61 (12), 2905-2914, 2020
宋珏， 路通， 谢林， 王广基， 刘晓东
中国临床药理学与治疗学 11 (12), 1350, 2006
|Determination of limonin in rat plasma by liquid chromatography–electrospray mass spectrometry|
Y Liang, L Xie, XD Liu, T Lu, GJ Wang, YZ Hu
Journal of pharmaceutical and biomedical analysis 39 (5), 1031-1035, 2005
|Integrated two‐analyte population pharmacokinetic model of polatuzumab vedotin in patients with non‐Hodgkin lymphoma|
D Lu, T Lu, L Gibiansky, X Li, C Li, P Agarwal, CS Shemesh, R Shi, ...
CPT: Pharmacometrics & Systems Pharmacology 9 (1), 48-59, 2020
|Semi‐mechanism‐based population pharmacokinetic modeling of the Hedgehog pathway inhibitor vismodegib|
T Lu, B Wang, Y Gao, M Dresser, RA Graham, JY Jin
CPT: Pharmacometrics & Systems Pharmacology 4 (11), 680-689, 2015
|Gender difference in ranolazine pharmacokinetics in rats|
XD Liu, L Xie, Y Liang, L Li, T Lu
European journal of drug metabolism and pharmacokinetics 28, 119-123, 2003
|Bayesian population model of the pharmacokinetics of venetoclax in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from …|
R Deng, L Gibiansky, T Lu, P Agarwal, H Ding, X Li, S Kshirsagar, D Lu, ...
Clinical Pharmacokinetics 58, 1621-1634, 2019